Palatin Technologies, Inc.

What they do

Palatin develops first-in-class medicines based on molecules that modulate the melanocortin receptor (MCR) system, targeting MC1R through MC5R. Its primary development focus is MC4R agonists for obesity, metabolic disorders, and rare MC4R pathway diseases such as hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome. Non-obesity activities focus on ocular, gastroenterology, and renal indications. The company's prior commercial product, Vyleesi, was sold to Cosette Pharmaceuticals in December 2023 and is now marketed by Cosette.

Revenue drivers

• License and collaboration agreements — Palatin's strategy is to develop product candidates and then form marketing collaborations with industry leaders, generating potential milestone, license, and royalty revenue rather than direct product sales.
• Boehringer Ingelheim agreement — In August 2025, Palatin entered a Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim for melanocortin receptor-targeted compounds for retinal diseases.
• Altanispac sublicense for PL9643 — In January 2026, Palatin entered an exclusive sublicense agreement with Altanispac Labs, LLC for PL9643, a clinical-stage MC1R agonist for dry eye disease.
• Vyleesi (historical) — Vyleesi was the company's only FDA-approved commercial product; it was acquired by Cosette in December 2023, after which Palatin reported no ongoing product revenue from it.

Recent performance

Annual revenue was $4.5 million in fiscal 2024 and $0.00 in fiscal 2025, and net loss was $17.3 million in fiscal 2025 versus a $29.7 million net loss in fiscal 2024. Operating cash flow was negative $21.3 million in fiscal 2025 and negative $31.5 million in fiscal 2024. For the quarter ended March 31, 2026, revenue was $3.9 million, following $116,036 in the December 2025 quarter and $8.8 million in the September 2025 quarter. As of March 31, 2026, total assets were $13.2 million, total liabilities $2.6 million, and shareholder equity $10.6 million, with $10.2 million in cash and equivalents.

Strategy

Palatin's stated strategy is to advance a differentiated portfolio of melanocortin receptor-targeted therapeutics, emphasizing MC4R agonists for rare neuroendocrine obesity disorders and other indications with significant unmet medical need. The company is developing MC4R selective long-acting peptide agonists and small molecule agonists. Non-obesity development focuses on ocular, gastroenterology, and renal indications, and Palatin says it is actively engaged in discussions with potential partners and licensees to progress those products. The company also maintains a lean, execution-oriented organization.

Risks

• Going concern uncertainty — Management has determined there is substantial doubt about Palatin's ability to continue as a going concern due to the need to raise significant additional financing to complete clinical trials, and the company has no commitments for additional financing.
• History of substantial net losses — Palatin had a net loss of $17.3 million for fiscal 2025 and an accumulated deficit of $459.1 million as of June 30, 2025, and expects to incur substantial net losses over the next few years.
• Dependence on partnering for commercialization — Palatin's strategy relies on forming marketing collaborations with industry leaders to maximize commercial potential, which may not materialize on acceptable terms or at all.
• Listing-rule failure and delisting notice — The company disclosed a delisting notice or listing-rule failure and Regulation FD disclosure in an 8-K filed May 18, 2026.

Outlook

Management expects to continue incurring significant expenses to develop its MC1R and MCR product candidates and states it will need substantial additional financing. The company's stated focus is advancing MC4R agonists for rare MC4R pathway diseases and obesity, while seeking partners for non-obesity programs. No specific revenue or earnings guidance is provided in the source material.